DFDS A/S
10.2.2021 07:49:29 CET | Globenewswire | Press release
Company announcement no. 6/2021
ANOTHER STRONG QUARTER FOR FREIGHT
• Passenger services remained restricted
• Freight earnings boosted by UK stockbuilding
• Mediterranean route network improved performance
• 2021 EBITDA outlook range of DKK 3.0-3.5bn
• Financial leverage, NIBD/EBITDA, expected to decrease in 2021
Q4 2020
• Q4 EBITDA on level with 2019
• Freight earnings up DKK 186m
• Free cash flow of DKK 444m
• NIBD/EBITDA lowered to 4.2
OUTLOOK 2021 (incl. HSF Logistics Group from 1 May)
• EBITDA of DKK 3.0-3.5bn
• Revenue growth of 20-25%
• Investments of around DKK 2.8bn
• NIBD/EBITDA to decrease around 0.5 ppt
"With the effects of Brexit and the pandemic hopefully soon behind us, our focus increasingly turns to delivering on our long-term growth ambitions," says Torben Carlsen, CEO.
| KEY FIGURES | ||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||
| DKK m | Q4 | Q4 | Change, % | Full year | Full year | Change, % | ||||||
| Revenue | 3,761 | 4,008 | -6.2 | 13,971 | 16,592 | -15.8 | ||||||
| EBITDA before special items | 769 | 771 | -0.2 | 2,732 | 3,633 | -24.8 | ||||||
| EBIT before special items | 289 | 257 | 12.5 | 858 | 1,751 | -51 | ||||||
| Profit before tax and special items | 194 | 181 | 7.2 | 583 | 1,472 | -60.4 | ||||||
| Profit before tax | 97 | 126 | -23.4 | 466 | 1,371 | -66 | ||||||
Revenue decreased 6% to DKK 3.8bn in Q4 and EBITDA before special items of DKK 769m was on level with 2019.
The result for freight ferry and logistics activities linked to the UK was boosted by extensive stockbuilding ahead of Brexit. In addition, volumes and earnings continued to improve in the Mediterranean business unit. Total EBITDA for freight ferry and logistics activities was DKK 186m above 2019 in Q4.
Tight travel restrictions were in place throughout Q4 and passenger volumes remained subdued in the quarter. In Q4, EBITDA for passenger services was DKK 186m below 2019. This result includes the passenger services in three business units – Passenger, Channel and Baltic Sea.
Outlook 2021
Uncertainty is elevated going into 2021 due to low visibility on the duration of travel restrictions linked to the pandemic. Longer term effects of Brexit have also yet to emerge. The acquisition of HSF Logistics Group is subject to regulatory approval but assumed consolidated from 1 May 2021.
On this background, revenue is expected to grow by 20-25% and EBITDA before special items is expected to be within a range of DKK 3.0-3.5bn (2020: DKK 2.7bn).
The outlook is detailed on page 9 in the full report.
Read the Q4 2020 Interim Report here:
https://www.dfds.com/en/about/investors/reports-and-presentations/q4-report-2020
10 February 2021. Conference call today at 10.00am CET
Access code: 81772821# Phone numbers to the call: DK +45 35445577, US +1 631 913 1422, UK +44 333 300 0804
Contact
Torben Carlsen, CEO +45 33 42 32 01
Karina Deacon, CFO +45 33 42 33 42
Søren Brøndholt Nielsen, IR +45 33 42 33 59
Nicole Seroff, Communications: +45 31 40 34 46
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S2.10.2026 19:49:50 CEST | Press release
Major Shareholder Announcement
HENLEY & PARTNERS GROUP HOLDINGS LTD2.10.2026 18:54:53 CEST | Press release
Henley & Partners - Argentina Announces New Citizenship by Investment Program
Unlimit Group A/S2.10.2026 18:05:13 CEST | Pressemeddelelse
Unlimit Group A/S: Indkaldelse til ekstraordinær generalforsamling
BONDUELLE2.10.2026 18:00:00 CEST | Press release
Bonduelle - 2025-2026 Annual results: The Bonduelle Group demonstrates its resilience, ending fiscal year 2025-2026 with stable sales and profitability
Biogen Inc.2.10.2026 17:20:00 CEST | Press release
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
